NOVOB80 Stock Price and Chart — SET:NOVOB80

Overview

Financials News Ideas Discussions Technicals Seasonals Bonds

Key facts today

Novo Nordisk cut its 2025 sales growth forecast to 8%-14% and operating profit to 10%-16%. Shares fell 30%, losing nearly $93 billion in market value.

Novo Nordisk has appointed Maziar Mike Doustdar as CEO, effective immediately. He aims to boost U.S. sales, especially for Wegovy, amid rising competition from Eli Lilly's Zepbound.

Novo Nordisk's CFO noted ongoing issues with illegal Semaglutide compounding, affecting Wegovy's consumer market presence, despite some positive trends in U.S. prescriptions.

Analyze the impact Analyze the impact

About NOVO NORDISK B A/S

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Check out other big names from the same industry as NOVOB80.